|
|
|
Volumn 16, Issue 8 Suppl 7, 2002, Pages 21-25
|
|
Mitomycin as a modulator of irinotecan anticancer activity.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DRUG DERIVATIVE;
IRINOTECAN;
MITOMYCIN;
ARTICLE;
CANCER STAGING;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG POTENTIATION;
FEMALE;
HUMAN;
MALE;
MAXIMUM TOLERATED DOSE;
MORTALITY;
NEEDLE BIOPSY;
NEOPLASM;
PATHOLOGY;
PATIENT SELECTION;
PHASE 1 CLINICAL TRIAL;
PROGNOSIS;
SURVIVAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BIOPSY, NEEDLE;
CAMPTOTHECIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG SYNERGISM;
FEMALE;
HUMANS;
MALE;
MAXIMUM TOLERATED DOSE;
MITOMYCIN;
NEOPLASM STAGING;
NEOPLASMS;
PATIENT SELECTION;
PROGNOSIS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0036675439
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (17)
|
|
References (0)
|
